Aptose TUSCANY trial advances to 160 mg TUS dose; receives additional $1.1M loan from Hanmi

Aptose Biosciences Inc.

CSRC approved escalation to 160 mg TUS dose after no dose-limiting toxicities at 40, 80, and 120 mg cohorts.
TUS+VEN+AZA triplet achieved CRs and MRD negativity in patients with adverse TP53 and FLT3-ITD mutations.
Aptose received $1.1M advance from Hanmi under $8.5M loan, bringing total advances to $5.6M.
Enrollment open for 160 mg cohort; all 120 mg patients remain on study.
Trial anticipates enrolling 18-24 patients by late 2025.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.